Here are four things to know:
1. The series A financing round was co-led by Amzak Health Investors and DSM Venturing. The NFL Players Association and additional investors also participated.
2. The company will use the proceeds to continue FDA-approved clinical trials of its first implant, the Bridge-Enhanced ACL Repair. The BEAR implant is designed to facilitate healing of a torn anterior cruciate ligament.
3. The BEAR technology is a proprietary bioengineered sponge used as a bridging scaffold to stimulate healing. It has been tested in nearly 100 patients.
4. According to Martha Murray, MD, founder of MIACH Orthopaedics and orthopedic surgery professor at Boston-based Harvard Medical School, the company will also use the funds to accelerate “clinical trials to further evaluate the less-invasive BEAR technology as a viable alternative to ACL reconstruction.”
More articles on biologics:
Spinal cord stem cells improve functional outcomes in animal SCI model: 3 study notes
Smart injectable self-setting orthopedic implant biocompatible, study finds
Regenexx affiliates with BICC to accelerate orthopedic stem cell treatments: 3 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
